Learn About Signatera™ Data for Each Use Case
Post-surgical ctDNA status identified study participants who benefited from an investigational adjuvant therapy1
Early decrease in ctDNA levels at week 6 correlated with favorable outcomes in the metastatic setting3
ctDNA dynamics in neoadjuvant setting can potentially support pathologic complete response (pCR) as surrogate endpoint4
Hear From Experts: Real World Uses
How can Signatera™ support your clinical trials?
Contact us to learn more
1 Powles T, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432-437. https://doi.org/10.1038/s41586-021-03642-9
2Oki E, Shirasu H, Watanabe J, et al. Dynamics of circulating tumor DNA after resection of colorectal cancer: Galaxy study in Circulate-Japan. Oral presentation presented at SSO, Dallas, Texas, March 9-12, 2022
3 Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020.1:873-881. https://doi.org/10.1038/s43018-020-0096-5
4Magbanua MJM, et al. Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229-239. https://doi.org/10.1016/j.annonc.2020.11.007
5Shoushtari, A, Collins, L, Arranz, E, et al. Early reduction in ctDNA regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients. Oral Presentation presented at ESMO GI; Sep 16-21, 2021. Abstract ID: 3600.
6 Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547-1557.